Open AccessNilotinib therapy after resistance and intolerance to imatinib in CML patient with trisomy of the chromosome 8
Author(s) -
Antonella Russo Rossi
Publication year - 2015
Publication title -
clinical management issues
Language(s) - English
Resource type - Journals
eISSN - 2283-3137
pISSN - 1973-4832
DOI - 10.7175/cmi.v4i5s.1095
Subject(s) - nilotinib , medicine , imatinib , chronic myeloid leukaemia , neutropenia , adverse effect , trisomy , first line therapy , first line , myeloid leukemia , oncology , genetics , chemotherapy , biology
In this article is presented the case of a 30-year-old woman with chronic myeloid leukaemia (CML) treated with imatinib for 15 months, and then with nilotinib as second-line therapy. Two episodes of grade 3 neutropenia, the detection of the trisomy of chromosome 8 and the failed achievement of a major molecular response (MMolR) in 15 months led to the switch to nilotinib. With nilotinib the patient obtained the lack of the genetic anomaly in 3 months and a complete molecular response (CMolR) in 6 months, all confirmed at 9 months. No haematologic or extra-haematologic adverse events were detected with this second-line agent.